FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3037746656> ?p ?o ?g. }

• W3037746656 endingPage "e15" @default.
• W3037746656 startingPage "e14" @default.
• W3037746656 abstract "To the Editor: Urinary tract infections are among the most common bacterial infections, with over 150 million annual cases globally.1 The most implicated bacterial species are Escherichia coli and other Enterobacteriaceae (Klebsiella and Proteus), Pseudomonas aeruginosa, and Staphylococcus aureus. Complicated urinary tract infection (cUTI) is defined if there are factors related to the host (e.g., immunosuppression, diabetes mellitus) or the urinary tract (e.g., obstruction or alterations of the detrusor muscle). An infection that involves the upper urinary tract (pyelonephritis) or causes a systemic involvement (urosepsis) can be considered a cUTI. The most recent data report an increase in the rates of uropathogenic resistant bacteria species. In the United States, from 2000 to 2009, the proportion of extended-spectrum beta-lactamases (ESBL)-producing Enterobacteriaceae in hospitalized patients with urinary tract infections has tripled.2 Many strains of E. coli are now producers of ESBL, and species resistant to fluoroquinolones and producer of ESBL is now widespread globally. Since the mortality rate from urosepsis has reached percentages ranging from 20% to 40%, new antibiotic drugs are more necessary than ever. On the other hand, carbapenem-resistant species are also increasing, constituting a danger that is currently difficult to address due to the absence of real pharmaceutical competitors: carbapenem-resistant strains of Klebsiella grew from 1% to 34% in the period 2006 to 2013.3 The need to spare carbapenems for severe infections has led the pharmaceutical industry to develop new association molecules capable of eradicating these multiresistant species. Ceftolozane-tazobactam (C/T) is a new combination of advanced cephalosporin and a beta-lactamase inhibitor. C/T is effective in the treatment of nosocomial pneumonia and intra-abdominal infections by Gram-negative bacteria. Ceftolozane-tazobactam is superior to levofloxacin in the treatment of cUTIs, as demonstrated by a multicenter trial, the ASPECT-cUTI, published in Lancet in 2015.4 We must point out that ASPECT-cUTI is a noninferiority trial. A noninferiority trial is often difficult to interpret and is based on assumptions often challenging to prove. Furthermore, the ASPECT-cUTI trial is the pooling of 2 different trials conducted in 2 different regions of the world: North and South America and Central and Eastern Europe. The authors did not specify whether the 2 populations are comparable in terms of drug resistance. C/T has not shown superiority over ceftazidime or piperacillin/tazobactam against cUTIs. The cost of these new molecules is often high: a pack of C/T costs around € 1000, a box of piperacillin/tazobactam around € 80, a box of meropenem € 60. Only a cost-benefit study in Taiwan compared C/T with piperacillin/tazobactam in terms of economic sustainability.5 The result was favorable for C/T. Although studies on this are lacking, the use of C/T is likely to be beneficial in the long term despite higher costs in the short term. For the reasons we mentioned, it would be desirable that the clinician was aware of the bacterial epidemiology of his hospital, primarily if he works in an intensive care unit. Remembering what the risk factors for a urinary infection with multidrug-resistant bacteria are is crucial: the age of the patient, an immunosuppressive condition, the presence of a urinary catheter, frequent hospitalization, or long-term hospitalization. The clinician must be aware of the difference between the severity of the infection and the multiresistance of the bacterial species. The 2 conditions are not necessarily associated, being able to develop very severe infections even for bacterial species sensitive to the primary empirical therapy. Furthermore, the clinician should distinguish hemodynamic instability due to a septic condition starting from a urinary infection, by a simple association between the 2 pathological conditions. Finally, the clinician should be able to interpret the antibiogram correctly, and especially know how to interpret the susceptibility profiles of a bacterial strain based on the correct reading of the MIC breakpoints. It should be noted that the MIC breakpoints are updated annually, and therefore, it is crucial, especially for intermediate susceptibilities, to be informed of the changes that have occurred. The collaboration between intensivists, microbiologist, and infectious disease specialist plays a fundamental role. The choice of an empirical therapy must be rational and motivated. Last but not least, the rapid deescalation based on the antibiogram result must be mandatory. Continuing (or shifting to a) treatment with an antibiotic for which the isolated species shows sensitivity, although more obsolete, is a well-documented strategy and able to save in terms of drug resistance and cheap. The C/T can provide an alternative to carbapenems for the treatment of infection caused by ESBL producers, thus allowing a carbapenems saving strategy while stratifying the correct patient setting and the relative place in therapy to prevent abuse. Daniele Orso, MD Anesthesia and Intensive Care Clinic Department of Anesthesia and Intensive Care Medicine ASUFC University-Hospital “Santa Maria della Misericordia” of Udine Udine, Italy Anesthesia and Intensive Care Clinic Department of Medicine University of Udine via Colugna 50, 33100 Udine, Italy [email protected]Francesco Cugini, MD Department of Emergency Medicine ASUFC Ospedale Sant’Antonio San Daniele del Friuli, Udine, ItalySergio Venturini, MDMassimo Crapis, MD Department of Infectious Diseases ASFO Ospedale Santa Maria degli Angeli Pordenone, ItalyManuela Lugano, MD Anesthesia and Intensive Care Clinic Department of Anesthesia and Intensive Care Medicine ASUFC University-Hospital “Santa Maria della Misericordia” of Udine Udine, ItalyLuigi Vetrugno, MDTiziana Bove, MD Anesthesia and Intensive Care Clinic Department of Anesthesia and Intensive Care Medicine ASUFC University-Hospital “Santa Maria della Misericordia” of Udine Udine, Italy Anesthesia and Intensive Care Clinic Department of Medicine University of Udine via Colugna 50, 33100 Udine, Italy" @default.
• W3037746656 created "2020-07-02" @default.
• W3037746656 creator A5002584089 @default.
• W3037746656 creator A5007166725 @default.
• W3037746656 creator A5007613609 @default.
• W3037746656 creator A5036390189 @default.
• W3037746656 creator A5044929790 @default.
• W3037746656 creator A5058646312 @default.
• W3037746656 creator A5089495155 @default.
• W3037746656 date "2020-07-01" @default.
• W3037746656 modified "2023-10-18" @default.
• W3037746656 title "A Bit of Caution in the Empirical Treatment of Complicated Urinary Tract Infections" @default.
• W3037746656 cites W1970599332 @default.
• W3037746656 cites W2013637885 @default.
• W3037746656 cites W2048550794 @default.
• W3037746656 cites W2936207141 @default.
• W3037746656 doi "https://doi.org/10.1097/ipc.0000000000000879" @default.
• W3037746656 hasPublicationYear "2020" @default.
• W3037746656 type Work @default.
• W3037746656 sameAs 3037746656 @default.
• W3037746656 citedByCount "0" @default.
• W3037746656 crossrefType "journal-article" @default.
• W3037746656 hasAuthorship W3037746656A5002584089 @default.
• W3037746656 hasAuthorship W3037746656A5007166725 @default.
• W3037746656 hasAuthorship W3037746656A5007613609 @default.
• W3037746656 hasAuthorship W3037746656A5036390189 @default.
• W3037746656 hasAuthorship W3037746656A5044929790 @default.
• W3037746656 hasAuthorship W3037746656A5058646312 @default.
• W3037746656 hasAuthorship W3037746656A5089495155 @default.
• W3037746656 hasBestOaLocation W30377466561 @default.
• W3037746656 hasConcept C104317684 @default.
• W3037746656 hasConcept C126322002 @default.
• W3037746656 hasConcept C177713679 @default.
• W3037746656 hasConcept C2776685102 @default.
• W3037746656 hasConcept C2777637488 @default.
• W3037746656 hasConcept C2778910516 @default.
• W3037746656 hasConcept C2779116282 @default.
• W3037746656 hasConcept C501593827 @default.
• W3037746656 hasConcept C523546767 @default.
• W3037746656 hasConcept C54355233 @default.
• W3037746656 hasConcept C547475151 @default.
• W3037746656 hasConcept C55493867 @default.
• W3037746656 hasConcept C71924100 @default.
• W3037746656 hasConcept C77411442 @default.
• W3037746656 hasConcept C86803240 @default.
• W3037746656 hasConcept C89423630 @default.
• W3037746656 hasConceptScore W3037746656C104317684 @default.
• W3037746656 hasConceptScore W3037746656C126322002 @default.
• W3037746656 hasConceptScore W3037746656C177713679 @default.
• W3037746656 hasConceptScore W3037746656C2776685102 @default.
• W3037746656 hasConceptScore W3037746656C2777637488 @default.
• W3037746656 hasConceptScore W3037746656C2778910516 @default.
• W3037746656 hasConceptScore W3037746656C2779116282 @default.
• W3037746656 hasConceptScore W3037746656C501593827 @default.
• W3037746656 hasConceptScore W3037746656C523546767 @default.
• W3037746656 hasConceptScore W3037746656C54355233 @default.
• W3037746656 hasConceptScore W3037746656C547475151 @default.
• W3037746656 hasConceptScore W3037746656C55493867 @default.
• W3037746656 hasConceptScore W3037746656C71924100 @default.
• W3037746656 hasConceptScore W3037746656C77411442 @default.
• W3037746656 hasConceptScore W3037746656C86803240 @default.
• W3037746656 hasConceptScore W3037746656C89423630 @default.
• W3037746656 hasIssue "4" @default.
• W3037746656 hasLocation W30377466561 @default.
• W3037746656 hasLocation W30377466562 @default.
• W3037746656 hasOpenAccess W3037746656 @default.
• W3037746656 hasPrimaryLocation W30377466561 @default.
• W3037746656 hasRelatedWork W1546431400 @default.
• W3037746656 hasRelatedWork W1577930419 @default.
• W3037746656 hasRelatedWork W1803350375 @default.
• W3037746656 hasRelatedWork W1968602861 @default.
• W3037746656 hasRelatedWork W1982073117 @default.
• W3037746656 hasRelatedWork W2036347073 @default.
• W3037746656 hasRelatedWork W2061297944 @default.
• W3037746656 hasRelatedWork W2076614389 @default.
• W3037746656 hasRelatedWork W2090280039 @default.
• W3037746656 hasRelatedWork W2898274243 @default.
• W3037746656 hasVolume "28" @default.
• W3037746656 isParatext "false" @default.
• W3037746656 isRetracted "false" @default.
• W3037746656 magId "3037746656" @default.
• W3037746656 workType "article" @default.